On the 12th, PlexBio announced a strategic partnership with Biomédica Equipamentos e Suprimentos Hospitalares Ltda. in Brazil. Through this collaboration, PlexBio's patented πCode diagnostic platform and molecular cancer mutation detection products will be distributed to medical centers and diagnostic institutions across Brazil via Biomédica Brazil. This partnership marks a significant milestone in promoting precision medicine in emerging markets by improving the accessibility of cancer genetic testing in Brazil.
As targeted cancer therapies become mainstream, the demand for companion genetic testing is rapidly increasing. However, the high costs of next-generation sequencing (NGS) technologies and related infrastructure pose significant barriers, particularly in developing countries. These countries face challenges in setting up fully compliant pathology laboratories (wet labs), establishing high-performance data analysis centers (dry labs), and providing sufficient local staffing, making precision medicine difficult to implement.
With PlexBio's patented πCode technology, automated diagnostic equipment can be operated by general lab technicians. The company’s lung cancer detection reagents can test tissue and liquid samples for genetic mutations in EGFR, BRAF, NRAS, KRAS, and PIK3CA genes. This allows Biomédica Brazil to distribute advanced diagnostic solutions to medical institutions in Brazil, enabling the public to access healthcare of the same quality as that in more developed nations.
As part of its expansion into developing markets, PlexBio has chosen Brazil as its starting point. Since January this year, PlexBio has supplied its lung cancer tissue detection reagents to the Precision Medicine Laboratory of Oncoclinicas Group (OCPM) for validation. The test results achieved 100% consistency. In a notable achievement, the research team at the São Paulo State Cancer Institute (ICESP), led by renowned scholar Dr. Evandro Sobroza de Mello, confirmed that PlexBio’s πCode® detection technology is an effective alternative to NGS. This research was presented at the 34th Brazilian Pathology Conference, where it won a prestigious award, providing strong validation for the reliability and accuracy of PlexBio’s technology.
Biomédica Brazil is committed to introducing innovative diagnostic technologies to Brazil, offering reliable, effective, and affordable high-quality products nationwide. Following certification by prominent cancer treatment institutions like OC Precision Medicine (OCPM), PlexBio hopes to further its efforts to make precision medicine more accessible across Brazil by promoting its validated products through Biomédica Brazil’s distribution channels and continuing verification at leading cancer treatment centers.
Dr. Carolyn Tsao, Chairman of PlexBio, stated: “PlexBio has long been committed to developing high-performance, user-friendly, and competitively priced in vitro diagnostic instruments and reagents to provide more patients with accessible, high-quality medical services. Our strategy for precision medicine is to complement advanced screening methods like NGS in developed nations while leveraging our cost-effective solutions in developing countries to enhance global accessibility and market penetration. In developed markets, we’ve already partnered with Japan's major testing company, Denka. This strategic collaboration with Biomédica Brazil not only strengthens PlexBio’s position but also aids in the promotion of precision medicine in developing markets, ultimately benefiting more patients.”
Resource (mandarin): 博錸生技與巴西 Biomédica Brazil 合作 攻精準醫療市場
